Visual hallucinations originating in the retinofugal pathway under clinical and psychedelic conditions
This theory building (2024) elucidates a new understanding of psychedelic modulation in the retinofugal pathway (between the eye and primary visual cortex). It suggests that disruptions in communication between cortical and subcortical regions, influenced by serotonin receptors, may lead to perceptual alterations and hallucinations.
Authors
- Kim Kuypers
- Johannes Ramaekers
Published
Abstract
Psychedelics like LSD (Lysergic acid diethylamide) and psilocybin are known to modulate perceptual modalities due to the activation of mostly serotonin receptors in specific cortical (e.g., visual cortex) and subcortical (e.g., thalamus) regions of the brain. In the visual domain, these psychedelic modulations often result in peculiar disturbances of viewed objects and light and sometimes even in hallucinations of non-existent environments, objects, and creatures. Although the underlying processes are poorly understood, research conducted over the past twenty years on the subjective experience of psychedelics details theories that attempt to explain these perceptual alterations due to a disruption of communication between cortical and subcortical regions. However, rare medical conditions in the visual system like Charles Bonnet syndrome that cause perceptual distortions may shed new light on the additional importance of the retinofugal pathway in psychedelic subjective experiences. Interneurons in the retina called amacrine cells could be the first site of visual psychedelic modulation and aid in disrupting the hierarchical structure of how humans perceive visual information. This paper presents an understanding of how the retinofugal pathway communicates and modulates visual information in psychedelic and clinical conditions. Therefore, we elucidate a new theory of psychedelic modulation in the retinofugal pathway.
Research Summary of 'Visual hallucinations originating in the retinofugal pathway under clinical and psychedelic conditions'
Introduction
Tipado and colleagues situate the paper in the longstanding effort to explain why classical serotonergic psychedelics such as LSD and psilocybin produce striking alterations in visual perception. Earlier work has emphasised cortical and subcortical loci of action—for example, visual cortex and thalamic gating mechanisms—but the mechanistic chain from early retinal processing to higher-level perceptual changes remains poorly specified. The authors note historical experimental claims that psychedelic-induced retinal activity can propagate to cortex and highlight clinical syndromes (e.g. Charles Bonnet syndrome) that produce hallucinations from visual-system pathology as potential pointers to under-explored peripheral contributions to psychedelic visuals. This paper sets out to synthesise anatomical, physiological and clinical evidence to propose that the retinofugal pathway—specifically interneurons in the retina called amacrine cells—may be a primary site at which psychedelics modulate visual signals before they reach thalamocortical circuits. The stated aim is to expand existing theories of psychedelic action (for example CSTC gating and REBUS predictive-coding models) by incorporating possible retinal modulation, and to articulate hypotheses and empirical observations that support a role for retinal serotonin-sensitive mechanisms in psychedelic visual phenomena.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Full Text PDF
Full Paper PDF
Pro members can view the original manuscript directly in the browser.
Study Details
- Study Typemeta
- Journal
- Authors
- APA Citation
Tipado, Z., Kuypers, K. P., Sorger, B., & Ramaekers, J. G. (2024). Visual hallucinations originating in the retinofugal pathway under clinical and psychedelic conditions. European Neuropsychopharmacology, 85, 10-20. https://doi.org/10.1016/j.euroneuro.2024.04.011
References (15)
Papers cited by this study that are also in Blossom
Cameron, L. P., Tombari, R. J., Lu, J. et al. · Nature (2020)
Carhart-Harris, R. L. · Neuropharmacology (2018)
Carhart-Harris, R. L., Erritzoe, D., Williams, T. et al. · PNAS (2012)
Carhart-Harris, R. L., Friston, K. J. · Pharmacological Reviews (2019)
De Araujo, D. B., Ribeiro, S., Cecchi, G. A. et al. · Human Brain Mapping (2011)
Dos Santos, R. G., Osório, F. L., Crippa, J. A. et al. · Neuroscience and Biobehavioral Reviews (2016)
Leptourgos, P., Fortier-Davy, M., Carhart-Harris, R. L. et al. · Schizophrenia Bulletin (2020)
Lewis, V., Bonniwell, E. M., Lanham, J. K. et al. · Cell Reports (2023)
Tófoli, L. F., De Araujo, D. B. · International Review of Neurobiology (2016)
Mason, N. L., Kuypers, K. P. C., Reckweg, J. et al. · Neuropsychopharmacology (2020)
Show all 15 referencesShow fewer
Lenz, C., Dolder, P. C., Lang, U. E. et al. · Acta Psychiatrica Scandinavica (2017)
Preller, K. H., Razi, A., Zeidman, P. et al. · PNAS (2019)
Roseman, L., Sereno, M. I., Leech, R. et al. · Human Brain Mapping (2016)
Timmermann, C., Roseman, L., Williams, L. et al. · Frontiers in Psychology (2018)
Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F. I., Bäbler, A. et al. · NeuroReport (1998)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.